Step Therapy Shifts and Pipeline Momentum Reshape the Membranous Nephropathy Treatment Landscape, according to Spherix Global Insights
Exton, PA., October 28, 2025 – The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of action and shifting away from legacy regimens, according to Spherix Global Insights’ recently published Market Dynamix™: Membranous Nephropathy (US) 2025 service. Nephrologists describe MN as one of the most complex kidney […]
Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation
Despite two recent FDA approvals, two-thirds of physicians report high unmet need in CSU, highlighting potential for clinical advancement, according to Spherix Global Insights. EXTON, PA, October 24, 2025 – Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients and healthcare providers in the […]
Hemophilia Specialists Raise the Bar: Quality of Life and Innovation Drive Market Reordering
New Spherix Global Insights data reveal growing physician demand for therapies that reduce treatment burden and elevate patient experience. EXTON, PA – October 22, 2025 — Hematologists across the United States are redefining what “success” looks like in hemophilia treatment, according to the latest findings from Market Dynamix™: Hemophilia (US) 2025 and the accompanying Launch […]
Sjögren’s Disease Remains an Underdiagnosed and Underguided Condition, Creating an Opening for Manufacturers to Shape the Future of Care, According to Spherix Global Insights
With multiple late-stage assets advancing, manufacturers have a near-term opportunity to drive much-needed disease education and shape therapeutic direction. EXTON, PA, October 16, 2025 – Sjögren’s Disease (SjD) continues to present significant diagnostic and therapeutic challenges within rheumatology, according to Spherix Global Insights’ Market Dynamix™: Sjögren’s Disease (US) 2025 report. Despite growing awareness and expanding […]
Spherix Global Insights Identifies Emerging Trends in Market Access Across More Than Twenty Key Therapeutic Areas
New payer research highlights tightening formularies, shifting contracting models, and rising cost-containment pressures heading into 2026. EXTON, PA, October 14, 2025 – Spherix Global Insights announces the release of Special Topix™: Payer Management Strategies, a comprehensive new analysis examining how U.S. health plans and pharmacy benefit managers (PBMs) are redefining access, contracting, and coverage decisions […]
Priovant’s Brepocitinib Poised to Address Steroid-Sparing Gap in Dermatomyositis as Rheumatologists Anticipate 2026 Launch
Physician sentiment captured in Spherix Global Insights’ research highlights high expectations for dual TYK2/JAK1 inhibition, with continued unmet needs across the broader IIM spectrum. EXTON, PA, October 10, 2025 – Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance for dermatomyositis (DM). According to Spherix Global […]
US Rheumatologists View Cell Therapy as a Potential Game Changer, with Systemic Sclerosis Emerging as the Most Compelling Indication, According to Spherix Global Insights
New research reveals cautious optimism as physicians weigh transformative potential against safety, access, and the enduring role of biologics and advanced systemics across rheumatic conditions. EXTON, PA, October 6, 2025 – Cell therapy may represent a new frontier in the treatment of autoimmune diseases, with the majority of US rheumatologists reporting highly favorable impressions of […]
Physicians Signal Cautious Enthusiasm for Gene Therapy Across Hematology, But Adoption Remains Selective
New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with practical barriers in sickle cell disease, thalassemia, and hemophilia. October 2, 2025 [Exton, PA] – According to the newly released Special Topix™: Adoption and Impact of Gene Therapy in Hematology, physicians across sickle cell disease […]
Spherix Global Insights Highlights Patient Influence in Shaping PNH Treatment Choices
Ultomiris (AZ/Alexion) and Empaveli (Appellis) identified as driving greater PNH treatment flexibility and individualized care Exton, Pa., September 26, 2025 – Spherix Global Insights today announced the latest quarterly update to its RealTime Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) service, revealing how patient requests and physician perspectives are reshaping the treatment landscape. This update highlights both the growing influence […]
Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology’s Future, According to Spherix Global Insights
As patients struggle with treatment burdens and suboptimal outcomes, new pipeline therapies spark hope for meaningful transformation across nAMD, DME, GA, and UME. Exton, PA, August 28, 2025 — In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S. ophthalmologists, including retina specialists, sheds light […]
